Clinical trial
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract…
NCT00101036 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00101036 |
|---|---|
| Title | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery |
| Official title | A Phase II Study of GW572016 (Lapatanib) in Locally Advanced or Metastatic Hepato-Biliary Cancers |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer |
| Intervention type | Drug, Other |
| Interventions | lapatinib ditosylate, laboratory biomarker analysis |
| Enrollment | 57 |
| Start date | Nov 1, 2004 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Jan 10, 2005 |
| Last update posted | Apr 20, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: